Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007.
about
The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-aTime trends in symptoms of mental illness in children and adolescents in CanadaUtilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.Gender and injuries predict stimulant medication use.Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-aIs adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.Temporal Trends in the Prevalence and Incidence of Diagnosed ADHD in Children and Young Adults between 1999 and 2012 in Canada: A Data Linkage Study.An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis.Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system.Long-Term Efficacy of Methylphenidate Immediate-Release for the Treatment of Childhood ADHD.Association of Risk of Suicide Attempts With Methylphenidate Treatment.New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.Participation restriction in childhood phenotype of myotonic dystrophy type 1: a systematic retrospective chart review.ADHD Treatment in Primary Care: Demographic Factors, Medication Trends, and Treatment Predictors.Demographic Characteristics and Psychiatric Comorbidity of Children and Adolescents Diagnosed with ADHD in Specialized Healthcare.Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015.Is ADHD Really Increasing in Youth?Psychotropic medicine prescriptions in Italian youths: a multiregional study.Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec.Pharmacological treatment of child and adolescent disruptive behaviour disorders: between the scylla and charybdis, what do the data say?ADHD Drug Prescribing Trend Is Increasing Among Children and Adolescents in Hong Kong.The relation between emotional intelligence and resilience in at-risk populations.The Prevalence of Attention Deficit/Hyperactivity Disorder among Chinese Children and Adolescents
P2860
Q26849779-BA5A2D45-48E4-42AA-9B3F-EA971CF42FFDQ30605931-3253D551-3D1A-4F5F-AB03-53F7D7609CCAQ31146596-5B9662E3-C8CB-41B8-8EF4-5439F4E1A426Q33782851-EA546DB5-6D8A-49D3-BD2F-0641A29B291CQ34575069-131F4590-2811-4A87-940B-B5FA1334DCF7Q35132674-7F22FB06-8B0F-45D8-B33F-D2F22446A5C1Q35896019-996D1ACB-6A68-4194-9EC5-BF9BC6705CE4Q36406035-50662E7F-10A6-44EC-96EB-17F2575D08C1Q36695980-1F9F072C-CA9C-4B2E-85BA-3C4EFC6E397EQ36756237-B91413F4-94DC-4DBA-A82E-90849327768FQ37525872-38C5A81F-4C03-4228-A09B-493F0E46FD09Q37648289-146A32FF-BDED-4F1C-97EB-6A91CB85B4B8Q38287037-11C917CC-0D0D-4F95-B14B-80CB26FE39DCQ38659993-7659AA27-571C-435C-B272-DDBD9FCC730CQ38764857-AD257E6B-27F3-42B2-921E-5B7C35A13F06Q38965173-7C88D5A6-27E7-4AB2-AEEA-54A21726864CQ39012500-2790FF1D-6A93-4D8B-9CAC-A786002B5FC4Q40509777-D8AE8E69-5DF7-4035-B962-1DBE6B7D729CQ40769095-FB4A6232-F44C-4258-808C-5623C85CDE7DQ40826720-4C1A22F0-D617-46B3-838C-337692186B4BQ40897841-B46CB775-7004-45F9-9392-DB0523C56AE2Q41869915-88CC21A4-A09D-4E87-B58A-3A6877A8E4DDQ42817814-03159B41-35DE-423B-8BB2-A45F70F3995EQ45176341-71C77EAF-E09D-4134-B60A-CABB0BC2B75FQ50304450-A8CB3412-C5BA-43B5-B5E0-84D3821732BEQ58774795-B62A15A3-A65D-43BF-9A14-3BA8EFF0A459
P2860
Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@en
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@nl
type
label
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@en
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@nl
prefLabel
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@en
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@nl
P2860
P1476
Prevalence of prescribed atten ...... chool-age children: 1994-2007.
@en
P2093
Marie-Christine Brault
Éric Lacourse
P2860
P304
P356
10.1177/070674371205700206
P407
P577
2012-02-01T00:00:00Z